Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Dolasetron. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR3A known ✓ | P46098 | 8/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 5/20 | 1.00 |
| ▸ | SLC6A4 | P31645 | 2/20 | 1.00 |
| ▸ | HTR3E | A5X5Y0 | 7/20 | 0.72 |
| ▸ | HTR3B | O95264 | 7/20 | 0.72 |
| ▸ | HTR3D | Q70Z44 | 7/20 | 0.72 |
| ▸ | HTR3C | Q8WXA8 | 7/20 | 0.72 |
| ▸ | HTR1A | P08908 | 2/20 | 0.72 |
| ▸ | HTR2B | P41595 | 2/20 | 0.72 |
| ▸ | HTR4 | Q13639 | 2/20 | 0.72 |
| ▸ | HTR1D | P28221 | 1/20 | 0.72 |
| ▸ | HTR1B | P28222 | 1/20 | 0.72 |
| ▸ | HTR2A | P28223 | 1/20 | 0.72 |
| ▸ | HTR2C | P28335 | 1/20 | 0.72 |
| ▸ | HTR1E | P28566 | 1/20 | 0.72 |
| ▸ | HTR1F | P30939 | 1/20 | 0.72 |
| ▸ | HTR7 | P34969 | 1/20 | 0.72 |
| ▸ | HTR5A | P47898 | 1/20 | 0.72 |
| ▸ | HTR6 | P50406 | 1/20 | 0.72 |
| ▸ | CHRNB2 | P17787 | 3/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Dolasetron SCHEMBL29356821 | 1.00 | HTR3A (1.00) | HTR3AKCNH2SLC6A4HTR3EHTR3B | |
| Dolasetron SCHEMBL14014817 | 1.00 | HTR3A (1.00) | HTR3AKCNH2SLC6A4HTR3EHTR3B | |
| Dolasetron SCHEMBL29390207 | 1.00 | HTR3A (1.00) | HTR3AKCNH2SLC6A4HTR3EHTR3B | |
| Dolasetron SCHEMBL13575734 | 1.00 | HTR3A (1.00) | HTR3AKCNH2SLC6A4HTR3EHTR3B | |
| Dolasetron SCHEMBL1819898 | 1.00 | HTR3A (1.00) | HTR3AKCNH2SLC6A4HTR3EHTR3B | |
| Dolasetron SCHEMBL42064 | 1.00 | HTR3A (1.00) | HTR3AKCNH2SLC6A4HTR3EHTR3B | |
| Dolasetron SCHEMBL24914047 | 1.00 | HTR3A (1.00) | HTR3AKCNH2SLC6A4HTR3EHTR3B | |
| Dolasetron SCHEMBL1819896 | 1.00 | HTR3A (1.00) | HTR3AKCNH2SLC6A4HTR3EHTR3B | |
| Dolasetron SCHEMBL14014809 | 1.00 | HTR3A (1.00) | HTR3AKCNH2SLC6A4HTR3EHTR3B | |
| Dolasetron SCHEMBL20769824 | 1.00 | HTR3A (1.00) | HTR3AKCNH2SLC6A4HTR3EHTR3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12622895-B2 | Anti-neurodegenerative combinations and use for treatment of neurodegenerative diseases | ALTO NEUROSCIENCE, INC. (US) | 2026-05-12 | — | — | US | disclosed |
| EP-4729123-A2 | COMPOSITIONS COMPRISING PRAMIPEXOLE AND A 5HT3 ANTAGONIST FOR USE IN TREATING DEPRESSION | Alto Neuroscience, Inc. (US) | 2026-04-22 | — | — | EP | disclosed |
| US-20260069573-A1 | COMBINATION THERAPY FOR A DOPAMINE AGONIST | ALTO NEUROSCIENCE INC (US) | 2026-03-12 | — | — | US | disclosed |
| EP-3615024-B1 | COMPOSITIONS COMPRISING PRAMIPEXOLE AND A 5HT3 ANTAGONIST FOR USE IN TREATING DEPRESSION | ALTO NEUROSCIENCE INC (US) | 2026-02-18 | — | — | EP | disclosed |
| US-12521374-B1 | Combination therapy for a dopamine agonist | ALTO NEUROSCIENCE, INC. (US) | 2026-01-13 | — | — | US | disclosed |
| US-12390454-B2 | Use and composition for protection against organophosphorus poisoning | CLARENCE SMITH KATHLEEN E (US) | 2025-08-19 | — | — | US | disclosed |
| US-11896582-B2 | Use and composition for treating myasthenia gravis and other myasthenic syndromes | DAS-MG, INC. (US) | 2024-02-13 | — | — | US | disclosed |
| US-11547700-B2 | Compositions and methods for treating synucleinopathies | CHASE THERAPEUTICS CORPORATION (US) | 2023-01-10 | — | — | US | disclosed |
| US-20220409599-A1 | USE AND COMPOSITION FOR PROTECTION AGAINST ORGANOPHOSPHORUS POISONING | CLARENCE SMITH KATHLEEN E (US) | 2022-12-29 | — | — | US | disclosed |
| US-11439630-B2 | Use and composition for protection against organophosphorus poisoning | CLARENCE SMITH KATHLEEN E (US) | 2022-09-13 | — | — | US | disclosed |
| US-9192591-B2 | Method and composition for treating alzheimer-type dementia | CHASE PHARMACEUTICALS CORPORATION (US) | 2015-11-24 | — | — | US | disclosed |
| US-20150133372-A1 | METHODS AND COMPOSITIONS FOR THE INDUCTION OF HYPOTHERMIA | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2015-05-14 | — | — | US | disclosed |
| US-8969297-B2 | Methods and compositions for the induction of hypothermia | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2015-03-03 | — | — | US | disclosed |
| US-20150004310-A1 | Purification of Nanocrystals by Gel Permeation Chromatography and the Effect of Excess Ligands on Shell Growth and Ligand Exchange | UNIVERSITY OF SOUTH CAROLINA | 2015-01-01 | — | — | US | disclosed |
| US-8877768-B2 | Method and composition for treating alzheimer-type dementia | CHASE PHARMACEUTICALS CORPORATION (US) | 2014-11-04 | — | — | US | disclosed |
| US-20140288057-A1 | METHOD AND COMPOSITION FOR TREATING ALZHEIMER-TYPE DEMENTIA | CHASE PHARMACEUTICALS CORPORATION (US) | 2014-09-25 | — | — | US | disclosed |
| US-20120282227-A1 | METHODS AND COMPOSITIONS FOR THE INDUCTION OF HYPOTHERMIA | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL | 2012-11-08 | — | — | US | disclosed |
| US-20120143119-A1 | Delivery of Serotonin Receptor Antagonists By Microinjection Systems | LANCO BIOSCIENCES, INC. (US) | 2012-06-07 | — | — | US | disclosed |
| US-20120143119-A1 | Delivery of Serotonin Receptor Antagonists By Microinjection Systems | LANCO BIOSCIENCES, INC. (US) | 2012-06-07 | — | — | US | disclosed |
| US-20090197823-A1 | ALISKIREN MODULATION OF NEUROGENESIS | BRAINCELLS, INC. (US) | 2009-08-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140288057-A1 | METHOD AND COMPOSITION FOR TREATING ALZHEIMER-TYPE DEMENTIA | ACHE, CHRNA3, BCHE | HTR3A 11/4885KCNH2 1330/4885SLC6A4 1332/4885 |
| US-20260069573-A1 | COMBINATION THERAPY FOR A DOPAMINE AGONIST | SLC6A3, SLC6A4, HTR4 | HTR3A 5/4885KCNH2 1178/4885SLC6A4 2/4885 |
| US-20090197823-A1 | ALISKIREN MODULATION OF NEUROGENESIS | DCX, NGF, BDNF | HTR3A 2030/4885KCNH2 3344/4885SLC6A4 1534/4885 |
| US-12622895-B2 | Anti-neurodegenerative combinations and use for treatment of neurodegenerative diseases | HTR1D, PARK7, HTR3A | HTR3A 3/4885KCNH2 1563/4885SLC6A4 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.